4. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 152 | Market Capitalization: $1.18 trillion
Strong Treatment Demand Meets the Challenge of Sustaining Growth
Eli Lilly and Company (NYSE: LLY) brings a healthcare growth story supported by substantial demand for diabetes and obesity treatments. In the second quarter of 2026, revenue increased 48% year over year to approximately $23.0 billion, driven primarily by higher volumes of Mounjaro and Zepbound.
The results show why investors continue to study the company among long-term healthcare stocks. Volume increased 60%, although a 13% reduction in realized prices partly offset that expansion. The distinction matters: treating more patients can support growth even as pricing becomes less favorable, but sustaining profitability requires careful management of production and commercial costs.
Eli Lilly and Company (NYSE: LLY) also raised its 2026 revenue guidance to between $85 billion and $87 billion in its August earnings release. That was a management forecast, with future performance dependent on demand, supply, pricing, and execution.
A 20-year thesis must extend beyond the success of current medicines. Manufacturing capacity, new indications, and future research could broaden the business, while competition, reimbursement restrictions, clinical setbacks, and patent expirations remain material risks. The investment case depends on converting scientific progress into a succession of commercially successful treatments.
Ranking Rationale
Eli Lilly and Company (NYSE: LLY) takes fourth place with 152 hedge fund holders. Demand for diabetes and obesity treatments, manufacturing expansion, and pharmaceutical research support its inclusion, while pricing pressure, competition, and clinical outcomes could influence future returns.
